BioFactura is on Course to Become a Global Leader in Biosimilar Development

BioFactura is on Course to Become a Global Leader in Biosimilar Development

Since the approval of the first biosimilar drug in the United States six years ago, the market has rapidly expanded and is expected to grow to approximately $23 billion in the U.S. by 2027. And Maryland’s BioFactura anticipates it will be one of the companies at the forefront of this revolution of new medications.

For the full article- see the link.

URL link to full story
https://biobuzz.io/biofactura-is-on-course-to-become-a-global-leader-in-biosimilar-development/
Media Contact
Jeffrey Hausfeld
(301) 792-8601
Comments are closed.